• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.

作者信息

Masarova Lucia, Cherry Mohamad, Newberry Kate J, Estrov Zeev, Cortes Jorge E, Kantarjian Hagop M, Verstovsek Srdan

机构信息

a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

b Department of Hematology and Oncology , The University of Oklahoma Stephenson Cancer Center , Oklahoma City , OK , USA.

出版信息

Leuk Lymphoma. 2016;57(1):237-9. doi: 10.3109/10428194.2015.1041392. Epub 2015 Sep 25.

DOI:10.3109/10428194.2015.1041392
PMID:25904378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4712116/
Abstract
摘要

相似文献

1
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.原发性血小板增多症和真性红细胞增多症患者的继发性实体瘤和淋巴瘤——单中心经验
Leuk Lymphoma. 2016;57(1):237-9. doi: 10.3109/10428194.2015.1041392. Epub 2015 Sep 25.
2
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.原发性骨髓纤维化中真性红细胞增多症和原发性血小板增多症后的第二原发性恶性肿瘤：对 2233 例患者的研究。
Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.
3
Running interferon interference in treating PV/ET: meeting unmet needs.干扰素干扰治疗 PV/ET：满足未满足的需求。
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):463-468. doi: 10.1182/hematology.2021000280.
4
The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.红细胞增多症或血小板增多症患者进展为真性红细胞增多症或原发性血小板增多症的发生率。
Ann Intern Med. 2003 Sep 16;139(6):470-5. doi: 10.7326/0003-4819-139-6-200309160-00009.
5
Summaries for patients. Polycythemia vera and essential thrombocythemia in a general population.
Ann Intern Med. 2003 Sep 16;139(6):I32. doi: 10.7326/0003-4819-139-6-200309160-00002.
6
Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症这两种骨髓增殖性疾病的流行病学
Semin Thromb Hemost. 2006 Apr;32(3):171-3. doi: 10.1055/s-2006-939430.
7
Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.原发性血小板增多症和真性红细胞增多症出血的发病机制与管理
Curr Hematol Rep. 2004 Sep;3(5):344-51.
8
Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).白消安与羟基脲治疗真性红细胞增多症（PV）和原发性血小板增多症（ET）的对比
Am J Clin Oncol. 1998 Feb;21(1):105-6. doi: 10.1097/00000421-199802000-00024.
9
Contemporary approach to essential thrombocythemia and polycythemia vera.原发性血小板增多症和真性红细胞增多症的现代治疗方法
Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216.
10
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.评估儿童和青年骨髓增生性肿瘤患者进行细胞减灭术的必要性及其潜在致癌性。
Ann Hematol. 2021 Oct;100(10):2567-2574. doi: 10.1007/s00277-021-04527-7. Epub 2021 Jul 30.

引用本文的文献

1
Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms.骨髓增殖性肿瘤患者发生第二恶性肿瘤的发病率和危险因素。
Cancer Med. 2023 Apr;12(8):9236-9246. doi: 10.1002/cam4.5666. Epub 2023 Feb 2.
2
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options.骨髓增殖性肿瘤治疗的新进展：当前和未来治疗选择的综述。
Medicina (Kaunas). 2021 Oct 31;57(11):1181. doi: 10.3390/medicina57111181.
3
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.芦可替尼治疗的真性红细胞增多症患者及其继发恶性肿瘤风险。
Ann Hematol. 2021 Nov;100(11):2707-2716. doi: 10.1007/s00277-021-04647-0. Epub 2021 Aug 31.
4
A Case Report of -Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib.一例对达沙替尼有完全血液学缓解和主要分子学缓解的阳性慢性髓性白血病病例报告
Case Rep Oncol. 2021 Apr 15;14(1):690-694. doi: 10.1159/000514632. eCollection 2021 Jan-Apr.
5
Invasive ductal breast carcinoma preceded by CALR-positive essential thrombocythemia.以CALR阳性原发性血小板增多症为前驱的浸润性导管乳腺癌。
Clin Case Rep. 2021 Feb 9;9(3):1732-1736. doi: 10.1002/ccr3.3892. eCollection 2021 Mar.
6
Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications.骨髓增殖性肿瘤患者发生实体瘤和淋巴瘤的风险：临床意义
Cancers (Basel). 2020 Oct 20;12(10):3061. doi: 10.3390/cancers12103061.
7
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.JAK抑制在骨髓纤维化治疗中的应用：局限性与未来展望
Hemasphere. 2020 Jul 21;4(4):e424. doi: 10.1097/HS9.0000000000000424. eCollection 2020 Aug.
8
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.原发性骨髓纤维化中真性红细胞增多症和原发性血小板增多症后的第二原发性恶性肿瘤：对 2233 例患者的研究。
Cancer Med. 2019 Aug;8(9):4089-4092. doi: 10.1002/cam4.2107. Epub 2019 Jun 7.
9
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.伴有或不伴有 JAK 抑制剂治疗的骨髓增生性肿瘤伴淋巴瘤患者的特征。
Blood. 2019 May 23;133(21):2348-2351. doi: 10.1182/blood-2019-01-897637. Epub 2019 Feb 22.
10
Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.并存的乳腺癌和原发性血小板增多症：我们如何应对治疗挑战。
Case Rep Hematol. 2018 Aug 12;2018:2080185. doi: 10.1155/2018/2080185. eCollection 2018.

本文引用的文献

1
Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.慢性骨髓增生性肿瘤与后续癌症风险：丹麦基于人群的队列研究。
Blood. 2011 Dec 15;118(25):6515-20. doi: 10.1182/blood-2011-04-348755. Epub 2011 Oct 28.
2
Higher risk of primary cancers after polycythaemia vera and vice versa.真性红细胞增多症后原发性癌症风险更高，反之亦然。
Br J Haematol. 2011 Apr;153(2):283-5. doi: 10.1111/j.1365-2141.2010.08538.x. Epub 2011 Jan 31.
3
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.费城染色体阴性骨髓增殖性肿瘤患者发生淋巴样肿瘤的风险增加。
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2068-73. doi: 10.1158/1055-9965.EPI-09-0353. Epub 2009 Jun 16.
4
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.原发性血小板增多症（ET）中的第二原发性恶性肿瘤：来自单一机构的331例长期随访患者的回顾性分析
Hematology. 2008 Aug;13(4):195-202. doi: 10.1179/102453308X316022.
5
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.真性红细胞增多症和原发性血小板增多症患者的预期寿命及生存预后因素。
Am J Med. 2004 Nov 15;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032.
6
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.接受白消安和羟基脲治疗的原发性血小板增多症患者的第二原发性恶性肿瘤：一项随机临床试验的长期随访
Br J Haematol. 2000 Sep;110(3):577-83. doi: 10.1046/j.1365-2141.2000.02188.x.